Dr. Jeffrey Glenn is a Professor of Medicine, Microbiology & Immunology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He is the founder of Eiger Biopharmaceuticals who is developing Lambda for hepatitis delta and COVID.

Dr. Glenn is an author on over 100 scientific articles and book chapters, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. He is the principal investigator on multiple NIH grants, and a member of FDA Antiviral Drugs.

He is an international authority on developing novel antiviral therapeutics.

Dr. Edward Pham receives his MD and Ph.D in Microbiology & Immunology from Stanford University.

His research focus is on novel antiviral therapies for current and emerging viral infections and the relationship between chronic viral infection and cancer including liver cancer through studying how the innate and adaptive immune system are perturbed in chronic viral infection.

He has been recognized by many prestigious awards such as National Research Service Fellowship from NIH for MD/PhD, Gates Millenium Scholar, Howard Hughes Medical Institute, International Achievement Summit Delegate.

Dr. Raymond F. Schinazi, PhD, Hon DSc, FAASLD, is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University. Dr. Schinazi holds a PhD in Chemistry from the University of Bath, England (1976). Dr. Schinazi has authored over 600 peer-reviewed papers and 7 books. He holds over 100 issued US patents, which have resulted in 28 New Drug Applications (NDA). Dr. Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs including FTC (emtricitabine), LdT (telbivudine), and sofosbuvir (Sovaldi). More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented. He is also the inventor of the use of baricitimid a JAK inhibitor for the treatment of COVID-19 patients. He is the recipient of numerous awards, including: 2018 France’s highest civilian honor, the Légion D’honneur, for saving millions of lives globally. Dr. Schinazi is internationally recognized as one of the most influential persons in the life science sector.

Wendy is the CEO of IMI.AI, a company that allow doctors to give medical advice to patients seamlessly. Wendy has a proven executive management track record with almost ten years of experience in the healthcare and business industry. Wendy was previously Co-founder/CEO of Med2lab, a startup focuses on innovating medical training. The system got adopted by Stanford School of Medicine.

Before that, she spent 5 years in the Management Team at Marin General Hospital, working closely with the CEO, Lee Domanico, as her mentor. Wendy also acts as the President and Founder of Apollo Care, a 501(c)3 nonprofit organization that provides free healthcare support to poor children oversea. She’s also an alumni of Y Combinator founder track, one of the top incubators in the world.

Wendy attended Graduate program from the University of California, San Francisco and a Bachelor Degree in Psychology from UMass Amherst.

Ms. Shekou has over 20 years of experience in real estate acquisitions and dispositions, commercial leasing, joint venture formations and commercial finance. She’s a major philanthropist and a Board Member of Marin Foundation and Marin Symphony.

Ms. Shekou is a member of American Bar Association and recognized numerous times as Super Lawyer in Northern California. She graduated with Highest Honors from University of California, Berkeley law and member of Phi Beta Kapa Honor Society.

Dr. Blaschke, is Professor of Medicine and of Molecular Pharmacology (Emeritus) at Stanford University, Adjunct Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF and Adjunct Professor of Medicine at Indiana University. From 2012 through 2015 he was a Senior Program Officer/Senior Advisor at the Bill and Melinda Gates Foundation and subsequently served as a consultant to the Foundation. Dr. Blaschke received his MD from Columbia University and did his residency training at UCLA. Following fellowship training in Clinical Pharmacology at UCSF he joined the Stanford faculty in 1974. He is past president of the American Society for Clinical Pharmacology and Therapeutics, recipient of the Oscar B. Hunter award from ASCPT and the 2014 Award in Excellence in Clinical Pharmacology from the PhRMA Foundation. He was a member of the AIDS Clinical Trials Group at its inception and served as chair of the Pharmacology Committee and a member of the Executive Committee. Much of his research has focused on HIV infection, emphasizing the modeling of exposure-response relationships and on medication adherence, especially in resource-limited settings. His involvement in clinical trials, with the FDA and with the pharmaceutical industry, has led to his interest in improving medication adherence and the efficiency of drug development using modeling and simulation. Dr. Blaschke has over 185 original publications and 75 reviews and chapters.